ClinicalTrials.Veeva

Menu

Immune Correlates of Cardiac Structure and Function

Duke University logo

Duke University

Status

Completed

Conditions

Perinatal HIV Infection
Cardiac Inflammation
Cardiac Fibrosis

Treatments

Diagnostic Test: Cardiac MRI

Study type

Observational

Funder types

Other
NIH

Identifiers

NCT05328713
Pro00109701
1R56HL152803-01 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The purpose of this study is to determine the occurrence of scarring of the heart (cardiac fibrosis) and inflammation in those with perinatally acquired Human Immunodeficiency Virus (HIV) infection compared to people not infected with HIV. The information learned from this research may help the investigator to better understand the link between cardiac fibrosis and cardiac dysfunction and inflammation in those with perinatally acquired HIV infection compared to the uninfected.

Participants will have a blood sample, complete a patient questionnaire, and have a Magnetic resonance imaging (MRI) and ultrasound of the heart.

Researchers will review the medical record and past medical history, for information about your heart function and overall health. Research samples and data from this study will be stored indefinitely and used for other research.

There are risks to participate in this study and those risks include side effects from the contrast agent used for the MRI scan, (such as headache and injection site pain), and risks from blood sampling.

Enrollment

40 patients

Sex

All

Ages

20 to 45 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Individuals 20-45 years of age
  2. Willingness and ability to provide signed and dated written informed consent, prior to any study-related procedures
  3. Diagnosed with HIV <10 years of age or physician confirmation of perinatal HIV infection
  4. On antiretroviral treatment (ART) for at least the last greater than or equal to 6 months
  5. Willingness to undergo Cardiovascular magnetic resonance imaging (CMR)
  6. Willingness to undergo echocardiogram (ECHO) (may be included if ECHO has been done at Duke in the previous 24 months).
  7. Willingness to have research blood draw

Exclusion criteria

  1. Contraindication to CMR (metal fragments in eyes or face, implanted electronic devices such as pacemakers, defibrillators, cochlear implants, or nerve stimulators, aneurysm clips)
  2. Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m2
  3. History of anaphylactic reaction to gadolinium contrast
  4. Inability to complete an MRI scan in the past due to anxiety
  5. Recent acute medical illness resulting in recent hospitalization (in past 90 days)
  6. History of: Coronary artery disease (CAD), Myocardial infarction (MI), moderate-severe valvular disease, congenital heart disease, heart failure, non-ischemic CM, Atrial fibrillation/flutter, implantable cardioverter defibrillator (ICD)/pacemaker, myocarditis prior
  7. Current Symptoms of Shortness of breath, severe chest pain, palpations, difficulty breathing on exertion, swelling of legs
  8. Known to be pregnant or current breastfeeding
  9. Known to be on hemodialysis
  10. Inability to breath hold for 5-10 seconds
  11. Known to have an ejection fraction <45% in the past 24 months
  12. Active cancer or cancer chemotherapy or radiation treatment in the prior year.
  13. Comorbid inflammatory disease, specifically treated for rheumatoid arthritis (RA) or lupus (SLE)
  14. Chronic use of steroids or anti-inflammatory therapy

Trial design

40 participants in 2 patient groups

Prospective group with perinatally acquired HIV infection from Duke University Health System clinics
Treatment:
Diagnostic Test: Cardiac MRI
Control retrospective group
Description:
A retrospective age- and sex-matched HIV-uninfected comparator group from Duke University Health System (DUHS) electronic health record (EHR) and imaging database systems

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems